Cellebrite DI (CLBT) AI Stock Analysis

• Market Cap: $4.43B
• Dividend Yield: N/A
• Average Volume (3M): 1.32M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: 20.48%
• EPS Growth: -44.22%
• Country: US
• Employees: 1,167
• Sector: Technology
• Sector Strength: 88
• Industry: Software - Infrastructure
• EPS (TTM): 0.08
• Shares Outstanding: 239,470,060
• 10 Day Avg. Volume: 1,102,388
• 30 Day Avg. Volume: 1,316,807
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 8.09
• Enterprise Value/Gross Profit: 9.59
• Enterprise Value/Ebitda: 48.79
• 1Y Price Target: $22.17
• Price Target Upside: 19.90% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 57 Neutral
• Price Target: $18.00 ▼(-2.65% Downside)

Cellebrite DI's overall stock score is driven by strong earnings call highlights, including significant ARR growth and strategic acquisitions, which contribute positively. However, financial performance challenges, particularly in profitability and valuation concerns due to a negative P/E ratio, weigh down the score. Technical analysis shows mixed signals, adding some uncertainty to the stock's short-term outlook.

Positive Factors

ARR Growth

Strong ARR growth indicates robust demand for Cellebrite's offerings, enhancing revenue predictability and supporting long-term financial stability.

Corellium Acquisition

Acquiring Corellium boosts Cellebrite's technological capabilities and market reach, particularly in defense and intelligence, fostering sustainable growth.

Cash Flow Strength

Strong cash flow generation enhances Cellebrite's ability to invest in growth initiatives, manage debt, and weather economic fluctuations.

Negative Factors

Profitability Challenges

Persistent profitability issues, reflected in negative margins, may hinder Cellebrite's ability to reinvest in the business and reward shareholders.

U.S. Federal Market Uncertainty

Uncertainty in federal spending could impact revenue projections and strategic planning, affecting Cellebrite's growth in a key market.

Modest Private Sector Performance

Slower growth in the private sector may limit Cellebrite's market expansion and revenue diversification, impacting long-term growth prospects.

Cellebrite DI Business Overview & Revenue Model

Company Description

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation. The company's Universal Forensic Extraction Device solution addresses problems in accessing digital information, including complicated device locks, encryption barriers, deleted and unknown content, and other obstacles that can prevent critical evidence from coming to light. It also offers Seeker solution that provides the ability to analyze video footage; OSINT Analyze, a real-time deep dive solution used to analyze open-source information, such as the surface web, deep web, and the dark web; and Crypto Tracer, which analyzes blockchain transactions together with related data from an extensive list of sources to identify and categorize wallets, and transactions. The company serves federal and state and local agencies, as well as enterprise companies and service providers. It has operations in the United States, Germany, Singapore, Australia, Brazil, United Kingdom, France, Canada, Japan, and India. The company was incorporated in 1999 and is based in Petah Tikva, Israel. Cellebrite Mobile Synchronization Ltd. operates as a subsidiary of Sun Corporation.

How the Company Makes Money

Cellebrite generates revenue primarily through the sale of its software and hardware products, including digital extraction devices and analytics tools. The company employs a subscription model for its software services, which provides ongoing revenue through annual licenses and renewals. Additionally, Cellebrite benefits from training and support services offered to its clients, which further contribute to its revenue streams. Key partnerships with government agencies, law enforcement bodies, and enterprises enhance its market presence, while the increasing demand for digital forensics solutions in various sectors, including cybersecurity, also drives its earnings.

Cellebrite DI Financial Statement Overview

Summary

Cellebrite DI shows strong gross margins and cash flow generation, but struggles with profitability and return on equity. The company maintains low leverage, which is positive for its financial health. Improving net income and return on equity is crucial for better financial performance.

Income Statement

Cellebrite DI shows a strong gross profit margin of 84.06% in TTM, indicating efficient cost management. However, the company is struggling with profitability, as evidenced by a negative net profit margin of -46.34%. Revenue growth is modest at 4.19% in TTM, which is a positive sign, but the sustained negative net income over the periods suggests challenges in achieving profitability.

Balance Sheet

The balance sheet reflects a low debt-to-equity ratio of 0.03 in TTM, indicating low leverage and financial stability. However, the return on equity is negative at -81.13%, highlighting inefficiencies in generating returns from equity. The equity ratio stands at 51.87%, suggesting a solid equity base relative to total assets.

Cash Flow

Cellebrite DI's cash flow statement shows a healthy free cash flow growth rate of 12.72% in TTM, indicating improved cash generation. The operating cash flow to net income ratio is 0.50, suggesting that operating cash flow is almost half of the net income, which is a positive sign. The free cash flow to net income ratio is high at 0.92, indicating strong cash flow relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	436.73M	401.20M	325.11M	270.65M	246.25M	194.91M
Gross Profit	368.50M	338.61M	271.88M	219.91M	203.69M	157.03M
EBITDA	72.43M	67.51M	-64.80M	10.24M	89.88M	16.95M
Net Income	-150.95M	-283.01M	-81.10M	120.81M	71.40M	5.78M
Balance Sheet
Total Assets	787.42M	690.57M	532.88M	403.29M	339.78M	364.39M
Cash, Cash Equivalents and Short-Term Investments	472.18M	447.22M	302.92M	183.62M	181.56M	237.64M
Total Debt	22.33M	10.97M	14.13M	15.36M	0.00	0.00
Total Liabilities	379.01M	354.55M	498.67M	329.43M	413.13M	300.58M
Stockholders Equity	408.41M	336.02M	34.21M	73.86M	-73.35M	63.80M
Cash Flow
Free Cash Flow	148.99M	121.56M	94.14M	11.49M	27.94M	60.33M
Operating Cash Flow	161.08M	132.17M	102.06M	20.58M	36.05M	66.51M
Investing Cash Flow	-120.54M	-149.47M	-22.54M	-91.23M	45.23M	-6.45M
Financing Cash Flow	29.70M	20.65M	21.77M	13.97M	-68.40M	-8.59M

Cellebrite DI Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 18.49
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLBT, the sentiment is Negative. The current price of 18.49 is below the 20-day moving average (MA) of 18.61, above the 50-day MA of 17.74, and above the 200-day MA of 18.05, indicating a bearish trend. The MACD of 0.08 indicates Positive momentum. The RSI at 41.13 is Neutral, neither overbought nor oversold. The STOCH value of 31.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLBT.

Cellebrite DI Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TUYA	―	$1.40B	47.73	2.89%	4.50%	22.46%	―
RDWR	―	$1.11B	80.86	4.46%	―	11.51%	―
EVTC	―	$1.88B	14.36	25.17%	0.64%	12.92%	101.57%
Sector *	―	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
VRNS	―	$3.62B	-31.92	-22.17%	―	11.37%	-34.44%
TENB	―	$3.47B	―	-12.60%	―	11.41%	33.76%
CLBT	―	$4.43B	―	-81.98%	―	20.48%	-44.22%

Cellebrite DI Corporate Events

Cellebrite DI Shareholders Approve Proposals at Annual Meeting

On September 19, 2025, Cellebrite DI Ltd. held its annual general meeting where shareholders approved all proposals presented, with approximately 76.82% of the ordinary shares represented. This approval signifies strong shareholder support and could enhance the company’s strategic initiatives and governance, potentially impacting its market positioning positively.

Cellebrite DI Announces Shareholder Meeting Amidst Strategic Growth and Leadership Changes

On August 15, 2025, Cellebrite DI Ltd. announced its upcoming Annual General Meeting of Shareholders scheduled for September 19, 2025. The company has made significant strategic progress over the past year, marked by strong financial performance in 2024, including a 25% increase in annual recurring revenue and a 23% rise in total revenue. The company is focused on expanding its customer base and product offerings, particularly in cloud and AI-powered solutions. Recent strategic moves include the acquisition of Corellium and the establishment of Cellebrite Federal Solutions. The company also announced a change in CFO, with David Barter taking over from Dana Gerner.

Cellebrite DI Reports Strong Financial Growth in H1 2025

Cellebrite DI Ltd. has released its unaudited consolidated financial statements for the six months ending June 30, 2025, showing a significant increase in total revenue to $220.8 million compared to $185.3 million in the same period last year. This financial growth reflects the company’s strengthened market position and its successful expansion in subscription services, which saw a notable rise in revenue, indicating a positive impact on its operations and stakeholder confidence.

Cellebrite Reports Strong Q2 2025 Results and Appoints New CEO

Cellebrite announced its second-quarter 2025 financial results, highlighting an 18% increase in revenue to $113.3 million and a 21% rise in annual recurring revenue to $418.9 million. The company appointed Thomas E. Hogan as CEO, who emphasized strategic progress, including the pending acquisition of Corellium and advancements in FedRAMP compliance. These developments are expected to enhance Cellebrite’s market position and drive growth in both public and private sectors.